Last Updated on May 14, 2024 by The Health Master
USFDA approval
Granules India, a leading pharmaceutical player, has secured a significant win with the US Food and Drug Administration approval (USFDA approval) for its Abbreviated New Drug Application (ANDA) for Colchicine Capsules (0.6 mg).
This USFDA approval, filed by Granules Pharmaceuticals, a wholly-owned subsidiary, marks a major step forward in providing patients with a new and potentially more affordable treatment option for gout.
Bioequivalent and Therapeutically Equivalent to Leading Brand:
The Granules India Colchicine Capsules are bioequivalent and therapeutically equivalent to Hikma International Pharmaceuticals’ Mitigare Capsules (0.6 mg), the current reference listed drug (RLD).
This signifies that Granules India’s capsules deliver the same amount of medication into the bloodstream and produce the same therapeutic effects as the brand-name drug.
Addressing a Growing Need: Gout Prevention in Adults
Gout is a painful condition caused by a buildup of uric acid crystals in the joints.
Colchicine is a well-established medication used to prevent gout flares (sudden attacks of intense joint pain and swelling) in adults.
The USFDA approval of Granules India’s Colchicine Capsules provides physicians with a new tool to manage gout in their patients.
Expanding Granules India’s USFDA Portfolio:
This approval strengthens Granules India’s position in the US market.
The company now boasts a total of 64 ANDA approvals from the USFDA, solidifying their commitment to developing and delivering high-quality generic medications to American patients.
Targeting a Lucrative Market:
The US market for Colchicine Capsules is estimated to be around $55 million annually (according to IQVIA/IMS Health data as of February 2024).
Granules India’s entry into this market with a potentially more affordable generic option could disrupt the current landscape and benefit both patients and healthcare providers.
Looking Ahead: Potential Impact
The USFDA approval of Granules India’s Colchicine Capsules is a positive development for several reasons:
- Increased Treatment Options: Patients with gout will have greater access to a medication that can help prevent painful flares.
- Enhanced Affordability: Generic medications typically cost less than brand-name drugs, potentially leading to cost savings for patients and healthcare systems.
- Market Competition: The introduction of a new generic player could stimulate competition and drive down overall costs for Colchicine capsules.
Granules India’s success with the USFDA is a testament to their commitment to innovation and patient care.
The company’s Colchicine Capsules have the potential to make a significant impact on the gout treatment landscape in the United States.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA Approval granted for Acetaminophen and Ibuprofen Tablets
USFDA approval granted for Loteprednol Etabonate Eye Drops
USFDA approval granted for this Eye Infection treatment
USFDA Approval granted for this Breast Cancer Drug: Alembic
USFDA approval granted for Fluoxetine Tablets
USFDA approval granted for First Generic Injection for Breast Cancer
India and Australia address issue of Pharma Pricing Control
Drug recall: Cipla, Glenmark recall these drugs
NPPA Reform Committee Includes Industry Representatives
USFDA Inspection: At Aurobindo Pharma Arm with 7 USFDA Observations
Pharmac South 2024 Gears Up for Special Conference on Revised Schedule M
New Ceiling Prices Announced for Coronary Stents in India
CDSCO-WHO Launches Virtual Webinar Series for Indian Regulators
Drug Export NOCs Now Handled by CDSCO
USFDA Approval granted for Acetaminophen and Ibuprofen Tablets
Drug recall: This Dietary Supplement recalled due to the Presence of Nortadalafil
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
